Quantcast
Home > Quotes > GNMX

Aevi Genomic Medicine, Inc. Common Stock (GNMX) Quote & Summary Data

GNMX 
$1.24
*  
0.03
2.36%
Get GNMX Alerts
*Delayed - data as of Jun. 15, 2018  -  Find a broker to begin trading GNMX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 1.2863 / $ 1.21
Share Volume
82,659
50 Day Avg. Daily Volume
99,096
Previous Close
$ 1.27
52 Week High / Low
$ 2.65 / $ 1.01
Market Cap
73,578,209
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
82,659
50 Day Avg. Daily Volume:
99,096

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.73

Trading Range

The current last sale of $1.24 is 22.77% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.2863 $ 2.65
 Low: $ 1.21 $ 1.01

Company Description (as filed with the SEC)

We are a clinical stage biopharmaceutical company with an emphasis on identifying the genetic drivers of disease and applying this understanding to the pursuit of differentiated novel therapies primarily for pediatric onset, life-altering diseases, including rare and orphan diseases. We look to find treatments for genetically defined diseases for which there are limited therapeutic options currently available, with a primary focus on pediatric patients. This strategy begins with identifying and genetically validating a therapeutic target and using genomics to guide product development. The strategy also involves identifying and acquiring otherwise abandoned or overlooked drug candidates and matching targets and mechanisms of action to novel genetic discoveries. We have partnered with the Center for Applied Genomics, or CAG, at The Children's Hospital of Philadelphia, or CHOP, to implement a genomic medicine driven approach to drug development.  ... More ...  

Risk Grade

Where does GNMX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.24
Open Date:
Jun. 15, 2018
Close Price:
$ 1.24
Close Date:
Jun. 15, 2018

Consensus Recommendation

Analyst Info